Engineered T cells as broad-spectrum antivirals

Immunocompromised individuals often have a number of active viral infections. Here, the development of an adoptive transfer strategy is presented, using multivirus-specific T cells (mVSTs) generated by direct stimulation of peripheral blood mononuclear cells with overlapping peptide libraries that incorporate antigens from five common viruses. The mVSTs were tested in a small clinical trial in recipients of allogenic transplants with up to four active infections, where they showed sustained and broad antiviral activity. Importantly, mVSTs can be rapidly produced and tailored to desired specifications.


  1. 1

    Papadopoulou, A. et al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci. Transl. Med. 6, 242ra83 (2014)

    Article  Google Scholar 

Download references


Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Flemming, A. Engineered T cells as broad-spectrum antivirals. Nat Rev Drug Discov 13, 654 (2014).

Download citation


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing